Home » Newsletters » BioWorld Science

BioWorld Science

March 17, 2011

View Archived Issues

Results disclosed from three phase I trials of darexaban

AstraZeneca begins phase III clinical program for NKTR-118

Inhibition of rRNA synthesis by CX-5461, a promising therapeutic strategy for cancer

Genomic rearrangements associated with transcriptional control implicated in prostate tumorigenesis

NO-releasing nanoparticles protect from hypovolemic shock effects

LEAD identifies novel Notch-sparing gamma-secretase inhibitors

New cannabinoid receptor modulators presented by Arena for pain

iTherX begins phase Ib study of ITX-5061 in HCV-infected liver transplant recipients

Array BioPharma and Genentech patent new B-raf inhibitors for cancer

Merck & Co. presents new muscarinic M1 receptor positive allosteric modulators

Merck & Co. patents novel beta3-adrenoceptor agonists for urinary disorders

Amylin and Takeda suspend pramlintide/metreleptin trial in obesity

RegeneRx's phase II RGN-352 trial in acute myocardial infarction on clinical hold

Nymox presents data from long-term NX-1207 trial in benign prostatic hyperplasia

Genfit and sanofi-aventis sign new agreement to develop drugs for metabolic disorders

Epistem and sanofi-aventis enter oncology biomarker collaboration

PsiOxus begins phase II study of MT-102 in cachexia

Human Genome Sciences acquires rights to anticancer drug FP-1039 from FivePrime

Athersys doses first patient in phase II trial of allogeneic cell therapy product MultiStem

Cortex regains all Ampakine assets and rights for respiratory depression

Cardiotrophin-1 enters phase I trial in Spain

Biotron completes first half of phase II trial of BIT-225 in HCV

Cytavis begins recruitment in Austria for phase II trial of CY-503 in colorectal carcinoma

Phosphagenics receives commitments for money to fund clinical trials and product rollouts

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 4, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 4, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Gene therapies aim for the big goal of edits in vivo
BioWorld Science
The field of gene therapy is experiencing major advances driven by precise editing technologies, such as base and prime editing, and by the design of increasingly...